January 26, 2015 12:08 PM ET

Biotechnology

Company Overview of Exosome Diagnostics, Inc.

Company Overview

Exosome Diagnostics, Inc. develops and commercializes biofluid based in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of oncologic, metabolic, and other diseases. It offers exosome-based minimally-invasive and body fluid molecular diagnostics. The company focuses on commercializing high sensitivity/specificity RNA in vitro diagnostic assays for use in disease recurrence monitoring and as companion diagnostics for use with targeted molecular therapies. The company has strategic collaborations with QIAGEN and Addario Lung Cancer Medical Institute. The company was formerly known as Exosome Theranostics, Inc. and changed its name to Exosome Diagnost...

840 Memorial Drive

Suite 3

Cambridge, MA 02139

United States

Founded in 2008

Phone:

617-588-0500

Key Executives for Exosome Diagnostics, Inc.

Chief Executive Officer
Age: 55
Chief Financial Officer
Age: 43
Chief Medical Officer
Vice President of Business Development
Director of Development and Services
Compensation as of Fiscal Year 2014.

Exosome Diagnostics, Inc. Key Developments

Exosome Diagnostics, Inc. and Addario Lung Cancer Medical Institute Announce Collaboration to Accelerate Development of Plasma-Based Lung Cancer Diagnostics

Exosome Diagnostics, Inc. announced a strategic collaboration with the Addario Lung Cancer Medical Institute (ALCMI) to accelerate the development of its lead plasma-based diagnostics in development for mutation detection and monitoring in patients with lung cancer. The collaboration will support validation of Exosome Diagnostics ALK and T790M lab developed tests (LDTs) planned to launch in 2015 and help advance future development of the company’s ALK and T790M in vitro diagnostic (IVD) kits. Exosome Diagnostics ALK and T790M tests have the potential to provide clinicians with real-time, precise molecular insights to help inform individualized treatment decisions for patients with lung cancer upon initial diagnosis and throughout the course of treatment. Exosome Diagnostics novel technology platform enables the development of tests that can analyze stable, high-quality exosomal RNA (exoRNA), representing a potentially important advance given that many known cancer mutations, such as gene arrangements and splice variants, are difficult or impossible to detect utilizing circulating DNA analysis.

Exosome Diagnostics Appoints Thomas McLain as Chief Executive Officer, Effective July 23, 2014

Exosome Diagnostics announced the appointment of Thomas McLain as its chief executive officer, effective July 23, 2014. Mr. McLain most recently was the CEO of Vermillion.

Exosome Diagnostics Appoints Vincent J. O'Neill as Chief Medical Officer

Exosome Diagnostics announced that Vincent J. O'Neill, M.D., has been appointed as its chief medical officer. Dr. O'Neill has extensive experience in clinical trial design, regulatory issues, and personalised medicine, most recently as global head personalised of Medicine and Companion Diagnostics at Sanofi. At Sanofi, he defined the personalised medicine strategy built the internal infrastructure and designed best practice protocols. He also created alliances and agreements with diagnostic testing laboratories and in vitro diagnostic companies. Prior to working at Sanofi, Dr. O'Neill managed the clinical development programs of several oncology therapeutic candidates, including biomarker development, at both Genentech and GlaxoSmithkline. He was instrumental in the expanded approval of products such as Avastin(R) and Tarceva(R) at Genentech. At GlaxoSmithkline, he managed the signal transduction discovery unit from which the first Investigative New Drug (IND) application and clinical trial, including patient selection strategy, of an MEK inhibitor (Mekinist(R)) was conducted.

Similar Private Companies By Industry

Company Name Region
Newco Tech, Inc. United States
Phage Pharmaceuticals, Inc. United States
Reviva Pharmaceuticals Inc. United States
Bridge to Life, Ltd. United States
Recros Medica, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 3, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Exosome Diagnostics, Inc., please visit www.exosomedx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.